Clinical trial · Observational
Elevated LDH Serum Levels and FDG-PET in Metastatic Melanoma Patients
NCT02949154CI-TRIAL-00076766completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A retrospective study investigating the relationship between FDG-PET uptake and LDH levels.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Metastatic melanoma patients
- description
- All patients \>18 years with histologically proven metastatic melanoma (American Joint Committee on Cancer \[AJCC\] stage IV melanoma) treated in the UMCG between May 2014 and December 2015.
Primary outcomes (1)
- measure
- Independent correlation between baseline serum LDH level and 18F-FDG uptake of tumour lesions
- timeFrame
- 3 months
Secondary outcomes (5)
- measure
- Correlation between baseline serum LDH level and tumour 18F-FDG uptake in subgroups separated by metastasis site
- timeFrame
- 3 months
- measure
- Correlation between baseline serum S100B level and tumour 18F-FDG uptake
- timeFrame
- 3 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: \- All patients \>18 years with histologically proven metastatic melanoma (American Joint Committee on Cancer \[AJCC\] stage IV melanoma) treated in the UMCG between May 2014 and December 2015. Exclusion Criteria: * participation in interventional studies * missing baseline 18F-FDG PET scan and/or baseline contrast enhanced CT scan * missing baseline serum LDH level * missing BRAF mutation status, concurrent malignancies or a history of previous malignancies.
References
Publications (0)
Data not yet available
No reference posted for this study.